RSS-Feed abonnieren
DOI: 10.1055/s-2004-828678
Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B
Publikationsverlauf
Publikationsdatum:
11. Juni 2004 (online)
![](https://www.thieme-connect.de/media/sld/2004S1/lookinside/thumbnails/10.1055-s-2004-828678-1.jpg)
Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents. Therefore, the recent European Association for the Study of the Liver (EASL) Consensus Committee recommended the use of interferon α for this condition. Treatment with pegylated interferons in several trials has shown better results still. Lamivudine in combination with interferon, however, did not improve the results at 6 months after the end of therapy. In HBeAg-negative chronic HBV infection, pegylated interferon α is superior to lamivudine, and, again, combination with lamivudine does not improve the results. Side effects in all studies have been tolerable. Thus, these observations in chronic HBV infection, whether HBeAg-positive or HBeAg-negative, suggest an important, even primary, role for pegylated interferon therapy.
KEYWORDS
Interferon - pegylated interferon alfa-2a (40 kD) - pegylated interferon alfa-2b (12 kD)
REFERENCES
- 1 Greenberg H B, Pollard R B, Lutwick L I et al.. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976; 295 517-522
- 2 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000. Summary of a workshop. Gastroenterology. 2001; 120 1828-1853
- 3 EASL International Consensus Conference on Hepatitis B . 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003; 38 533-540 , (review)
- 4 Manns M P. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis. 2002; 22(Suppl 1) 7-13
- 5 Conjeevaram H S, Lok A S-F. Management of chronic hepatitis B. J Hepatol. 2003; 38 S90-S103
- 6 Cooksley W G. Treatment of hepatitis B with interferon and combination therapy. Clin Liver Dis N Am. 2004; , (In press)
- 7 Wong D K, Cheung A M, O'Rourke K et al.. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119 312-323
- 8 Craxi A, Di Bona D, Camma C. Interferon alpha for HBeAg positive chronic hepatitis B: systematic review. J Hepatol. 2003; 39(Suppl 1) 99-105
- 9 Bortolotti F, Jara P, Barbera C et al.. Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000; 46 715-718
- 10 Fattovich G, Giustina G, Sanchez-Tapias J et al.. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998; 93 896-900
- 11 Lau D T, Everhart J, Kleiner D E et al.. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997; 113 1660-1667
- 12 Lin S M, Sheen I S, Chien R N et al.. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29 971-975
- 13 Lok A S, Chung H T, Liu V W, Ma O C. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993; 105 1833-1838
- 14 Lok A SF, McMahon B J. Chronic hepatitis B. Hepatology. 2001; 34 1225-1241
- 15 Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EURHEP) Executive Team on Anti-Viral Treatment. J Viral Hepat. 1998; 5 389-397
- 16 Thomas H C, Lok A SF, Carreno V et al.. Comparative study of three doses of interferon alfa-2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat. 1994; 1 139-148
- 17 Janssen H L, Gerken G, Carreno V et al.. Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1999; 30 238-243
- 18 Cohard M, Poynard T, Mathurin P et al.. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology. 1994; 20 1390-1398
- 19 Kao J H, Wu N H, Chen P J et al.. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000; 33 998-1002
- 20 Zhang X, Zoulim F, Habersetzer F et al.. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol. 1996; 48 8-16
- 21 Hoofnagle J H, Di Bisceglie A M, Waggoner J G, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993; 104 1116-1121
- 22 Perrillo R, Tamburro C, Regenstein F et al.. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995; 109 908-916
- 23 Janssen H L, Schalm S W, Berk L et al.. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol. 1993; 17(Suppl 3) S47-S51
- 24 Carreno V, Marcellin P, Hadziyannis S et al.. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1999; 30 277-282
- 25 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology. 2001; 121 101-109
- 26 Brunetto M R, Oliveri F, Coco B et al.. The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002; 36 263-270
- 27 Lampertico P, Del Ninno E, Manzin A et al.. A randomized controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997; 26 1621-1625
- 28 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001; 34 306-313
- 29 Oliveri F, Santantonio T, Bellati G et al.. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol. 1999; 94 1366-1372
- 30 Cooksley W GE, Lai M-Y, Piratvisuth T et al.. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10 298-305
- 31 Cooksley W GE, Lai M-Y, Piratvisuth T et al.. Treatment with peginterferon alfa-2a (40kD) (Pegasys) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B, including HBV genotypes B or “difficult to treat” genotype C. J Hepatol. 2003; 38 52 , (abst)
- 32 Niederau C, Heintges T, Lange S et al.. Long-term follow-up HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996; 334 1422-1427
- 33 Liaw Y-F, Chow W C, Shue K et al.. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology. 2003; 38(Suppl 1) 262A
- 34 Hadziyannis S, Tassopoulos N, Heathcote J et al.. 96 weeks of adefovir dipivoxil in HBeAg negative chronic hepatitis B: significant virological, biochemical and histological improvement. Presented at the 11th International Symposium on Viral Hepatitis in Liver Disease April 5-8, 2003 Sydney, Australia;
- 35 Chang T T, Lim S G, Hadziyannis S et al.. Long-term safety of adefovir dipivoxil 10 mg once daily in chronic hepatitis B: an integrated analysis of two phase III studies. J Hepatol. 2003; 38(Suppl 2) 133A
- 36 Mutimer D, Naoumov N, Honkoop P et al.. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol. 1998; 28 923-929
- 37 Schiff E R, Karayalcin S, Grimm I et al.. A placebo controlled study of lamivudine and interferon α-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology. 1998; 28 388A
- 38 Schalm S W, Heathcote J, Cianciara J et al.. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000; 46 562-568
- 39 Barbaro G, Zechini F, Pellicefli A M et al.. Long-term efficacy of alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with hepatitis B. An Italian multicenter randomized trial. J Hepatol. 2001; 35 406-411
- 40 Sanantonio T, Niro G A, Sinisi E et al.. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J Hepatol. 2002; 36 799-804
- 41 Sung J JY, Chan H LY, Hui A Y et al.. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B-a randomized trial. J Hepatol. 2003; 38(Suppl 2) 33A
- 42 Janssen H LA, Senturk H, Zeuzum S et al.. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients. Hepatology. 2003; 38(Suppl 1) 246A
- 43 Marcellin P, Lau G KK, Bonino F et al.. A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40kD) (Pegasys®) alone or in combination with lamvudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. Hepatology. 2003; 38(Suppl 1) 724A
- 44 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347 975-982
Professor
Graham Cooksley
Department of Medicine, The University of Queensland
C8 Clinical Sciences Building, Royal Brisbane Hospital
Queensland, Australia 4029
eMail: grahamC@qimr.edu.au